Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with previously untreated higher-risk myelodysplastic syndromes, did not meet its primary endpoint of overall survival at the final analysis.
The companies noted that the safety profile of the Venclexta combination was consistent with the known risk of the individual study medicines and no unexpected safety signals were observed.
According to the companies, the results of the VERONA study have no impact on the approved indications for Venclexta or any ongoing studies.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.